XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements [Yahoo! Finance]
Zevra Therapeutics, Inc. (ZVRA)
Company Research
Source: Yahoo! Finance
million milestones, in full year 2025 • Total receipts increased 9% with royalties up 68% versus full year 2024 Business development : Added 22 assets to portfolio, including five programs in Phase 2 or Phase 3 development Stock buyback program : Repurchased and retired 648,048 shares for an aggregate of $16.0 million Company acquisitions : Completed seven acquisitions, accumulating $11.7 million of non-dilutive capital , economic interests of approximately 25% in up to $1.1 billion of milestones and low to mid-single digit royalties from eight partnered programs Key 2026 pipeline events : • Phase 2b data from volixibat in PSC in Q2 and Phase 3 data from ersodetug in tumor HI in 2H • Potential for EMA decisions on OJEMDA™ and MIPLYFFA™ marketing authorization applications • Regulatory updates related to ersodetug in congenital HI and seralutinib in PAH Webcast at 8:00 am Eastern Time today EMERYVILLE, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NAS
Show less
Read more
Impact Snapshot
Event Time:
ZVRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ZVRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ZVRA alerts
High impacting Zevra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ZVRA
News
- Zevra Ties NPC Testing Push To Valuation Gap And New CFO [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Zevra Therapeutics (ZVRA) is now covered by BTIG Research. They set a "buy" rating and a $23.00 price target on the stock.MarketBeat
- Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million [Yahoo! Finance]Yahoo! Finance
ZVRA
Earnings
- 3/9/26 - Beat
ZVRA
Sec Filings
- 3/19/26 - Form 4
- 3/19/26 - Form 3
- 3/16/26 - Form 144
- ZVRA's page on the SEC website